Value Assessment & Pricing in France, the UK and Germany

Aims and objectives:
Harmonisation of the drug value assessment in Europe still has far to go. The most promising projects to date are related to Multi-HTA early dialogues.

This meeting gives you an up-to-the-minute update on the harmonisation efforts as well as on national value assessment and pricing in France, Germany and the UK.
- What is the role of health economics in the different systems?
- How are orphan drugs, cancer drugs and drugs for chronic diseases assessed?

After having attended this meeting you will be aware of the current status of and the challenges for the national systems in the UK, France and Germany, and have a sound perspective on what you can expect from the European HTA cooperations.

Topics:
- National versus Multi-HTA early dialogues
- Drug assessment by the French HAS - introduction of health economics
- Drugs for rare diseases - the NICE perspective
- Pricing in the UK - How this relates to market access success